Onno van de Stolpe - Galapagos NV - Co-Founder, CEO, MD and Executive Director
Okay, Sandra. On other clinical indications, so as we said before, we drive -- it's our strategy to do more than 1 proof of concept clinical study with
every novel modeof action, so we are actively looking currently which is going to be the second indication. It will be too soon to report on that
today but I can tell you, we are running a number of animal models. And over the coming months, we'll let you know which is the second indication.
Nog voor einde jaar, start studie met glpg1690 in tweede indicatie, wss lever..